Utama › Kanser Paru-paru Sel Kecil › Florida › Orlando
Kajian klinikal Kanser Paru-paru Sel Kecil di Orlando, FL
15 kajian untuk Kanser Paru-paru Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Orlando (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Advent Health, Orlando
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1
- AdventHealth Cancer Institute, Orlando
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Orlando Health Cancer Institute /ID# 280418, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Sara Cannon Research Institute Lake Nona, Orlando
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Mengambil pesertaFasa 3
- University of Florida Health Cancer Center at Orlando Health, Orlando
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Mengambil pesertaFasa 3
- Clermont Oncology Center, Clermont · 24 mi jauh
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, Orlando
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Clermont Oncology Center, Clermont · 24 mi jauh
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- AdventHealth Celebration, Celebration · 17 mi jauh
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Mengambil pesertaFasa 3
- AdventHealth Orlando, Cancer Institute, Orlando
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Florida Cancer Specialists, Orlando
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of LY4175408 in Participants With Advanced Cancer
Mengambil pesertaFasa 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi jauh
Kajian Kanser Paru-paru Sel Kecil di bandar lain
- Houston, TX26 kajian
- Arlington, VA23 kajian
- Boston, MA21 kajian
- New York City, NY21 kajian
- Nashville, TN20 kajian
- Los Angeles, CA20 kajian
- Dallas, TX13 kajian
- St. Louis, MO13 kajian
- Cleveland, OH13 kajian
- Detroit, MI12 kajian
- Chicago, IL12 kajian
- Washington, DC12 kajian
Kajian lain di Orlando
- Kanser Paru-paru Bukan Sel Kecil44 kajian
- Obesiti31 kajian
- Kanser Metastatik29 kajian
- Berat Badan Berlebihan27 kajian
- Penyakit Alzheimer25 kajian
- Diabetes Jenis 224 kajian
- Kanser (semua jenis)24 kajian
- Kanser Payudara23 kajian
- Kanser Ovari22 kajian
- Kolitis Ulseratif22 kajian
- Kanser Paru-paru21 kajian
- Kanser Kolorektal19 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.